|
UBE2J1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.68539999962003E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.351700E-04 |
| Normal-vs-Stage2 |
1.3285000000085E-06 |
| Normal-vs-Stage3 |
3.21419999504968E-08 |
| Normal-vs-Stage4 |
1.33529999946091E-07 |
| Stage1-vs-Stage2 |
3.819400E-03 |
| Stage1-vs-Stage3 |
8.750000E-04 |
| Stage1-vs-Stage4 |
3.208800E-04 |
| Stage2-vs-Stage3 |
8.930400E-01 |
| Stage2-vs-Stage4 |
4.441400E-01 |
| Stage3-vs-Stage4 |
5.104600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.41070000020594E-07 |
| Normal-vs-AfricanAmerican |
2.723400E-03 |
| Normal-vs-Asian |
1.399560E-02 |
| Caucasian-vs-AfricanAmerican |
8.473800E-01 |
| Caucasian-vs-Asian |
2.122000E-01 |
| AfricanAmerican-vs-Asian |
3.599600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.62939999954249E-07 |
| Normal-vs-Female |
2.42770000002945E-06 |
| Male-vs-Female |
2.950000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.042800E-03 |
| Normal-vs-Age(41-60Yrs) |
6.97299999963263E-07 |
| Normal-vs-Age(61-80Yrs) |
1.68589999960389E-07 |
| Normal-vs-Age(81-100Yrs) |
1.525350E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.588400E-04 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.300160E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.184000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.564000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.542800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.065800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.726300E-02 |
| Classical-VS-Follicular |
1.387540E-02 |
| Classical-VS-Other |
2.043800E-01 |
| Classical-VS-Normal |
4.25419999999788E-05 |
| Tall-VS-Follicular |
9.230800E-01 |
| Tall-VS-Other |
6.715000E-01 |
| Tall-VS-Normal |
8.15620000000905E-05 |
| Follicular-VS-Other |
6.640600E-01 |
| Follicular-VS-Normal |
5.53160000027475E-07 |
| Other-VS-Normal |
1.106250E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.95749999987171E-07 |
| Normal-vs-N1 |
1.62562999999061E-05 |
| N0-vs-N1 |
5.357200E-01 |
|
|
